VBI Vaccines Updates Share Sale Agreements and Partnerships

VBI Vaccines (VBIV) has issued an update.

VBI Vaccines Inc. has engaged with H.C. Wainwright & Co. to potentially sell up to $8,468,289 worth of common shares in an at-the-market offering, following a registration statement effective since September 2022. The company could use the proceeds for general corporate purposes, with Wainwright earning a 3% commission on sales. This new agreement follows the termination of a previous arrangement with Jefferies LLC, which could have seen sales up to $125 million, and carries no penalties for the company.

See more data about VBIV stock on TipRanks’ Stock Analysis page.